Preliminary clinical outcomes of patients treated with vaginal brachytherapy alone using multi-channel vaginal brachytherapy applicator in operated early-stage endometrial cancer.
brachytherapy
endometrium
multichannel brachytherapy applicator
Journal
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
ISSN: 1507-1367
Titre abrégé: Rep Pract Oncol Radiother
Pays: Poland
ID NLM: 100885761
Informations de publication
Date de publication:
2021
2021
Historique:
received:
17
02
2020
accepted:
24
12
2020
entrez:
5
5
2021
pubmed:
6
5
2021
medline:
6
5
2021
Statut:
epublish
Résumé
Recommendations for adjuvant treatment for postoperative, early-stage endometrial cancer varies from observation through vaginal brachytherapy alone to pelvic radiation. While observation alone can lead to recurrence, external radiotherapy has increased morbidity. The aim of this study is to show our results with vaginal brachytherapy alone using a multichannel applicator for treatment of early-stage endometrial cancer. Consecutive patients undergoing vaginal brachytherapy alone following surgery for early-stage endometrial cancer were examined. A Miami multichannel vaginal brachytherapy applicator was used to deliver HDR brachytherapy in 62 patients from May 2013 to June 2018. CT scan-based images guided planning. A dose of 5.5-6.5 Gy × 4 fractions was prescribed 5 mm from the surface of the applicator. At a median follow up of 19 months (6-48 months), 93% of patients treated were alive with no recurrence. Two patients had only local recurrence, and 1 was salvaged with external radiotherapy and chemotherapy. There was only one nodal failure and 2 distant failures. There was no grade 2 or higher vaginal, gastrointestinal or genitourinary toxicity. Vaginal brachytherapy alone using a multichannel applicator can be considered for early-stage endometrial cancers without compromising outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Recommendations for adjuvant treatment for postoperative, early-stage endometrial cancer varies from observation through vaginal brachytherapy alone to pelvic radiation. While observation alone can lead to recurrence, external radiotherapy has increased morbidity. The aim of this study is to show our results with vaginal brachytherapy alone using a multichannel applicator for treatment of early-stage endometrial cancer.
MATERIALS AND METHODS
METHODS
Consecutive patients undergoing vaginal brachytherapy alone following surgery for early-stage endometrial cancer were examined. A Miami multichannel vaginal brachytherapy applicator was used to deliver HDR brachytherapy in 62 patients from May 2013 to June 2018. CT scan-based images guided planning. A dose of 5.5-6.5 Gy × 4 fractions was prescribed 5 mm from the surface of the applicator.
RESULTS
RESULTS
At a median follow up of 19 months (6-48 months), 93% of patients treated were alive with no recurrence. Two patients had only local recurrence, and 1 was salvaged with external radiotherapy and chemotherapy. There was only one nodal failure and 2 distant failures. There was no grade 2 or higher vaginal, gastrointestinal or genitourinary toxicity.
CONCLUSION
CONCLUSIONS
Vaginal brachytherapy alone using a multichannel applicator can be considered for early-stage endometrial cancers without compromising outcomes.
Identifiants
pubmed: 33948301
doi: 10.5603/RPOR.a2021.0007
pii: rpor-26-1-43
pmc: PMC8086707
doi:
Types de publication
Journal Article
Langues
eng
Pagination
43-49Informations de copyright
© 2021 Greater Poland Cancer Centre.
Déclaration de conflit d'intérêts
Conflicts of interest There are no relevant conflicts of interest.
Références
J Appl Clin Med Phys. 2013 Jan 07;14(1):4098
pubmed: 23318396
South Asian J Cancer. 2016 Jul-Sep;5(3):112-20
pubmed: 27606294
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Gynecol Oncol. 1999 Oct;75(1):103-7
pubmed: 10502434
J Clin Oncol. 2011 May 1;29(13):1692-700
pubmed: 21444867
J Natl Cancer Inst. 2012 Nov 7;104(21):1625-34
pubmed: 22962693
J Contemp Brachytherapy. 2012 Dec;4(4):247-52
pubmed: 23378855
Gynecol Oncol. 2005 Jun;97(3):887-92
pubmed: 15943991
Lancet. 2009 Jan 10;373(9658):137-46
pubmed: 19070891
J Clin Oncol. 2009 Jul 20;27(21):3547-56
pubmed: 19546404
Gynecol Oncol. 2003 May;89(2):288-94
pubmed: 12713993
Gynecol Oncol. 2017 Mar;144(3):515-523
pubmed: 28017306
Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):417-25
pubmed: 10661349
Gynecol Oncol. 2018 Aug;150(2):293-299
pubmed: 29929925
Gynecol Oncol. 2013 Dec;131(3):604-8
pubmed: 24055615
Gynecol Oncol. 2010 Mar;116(3):404-7
pubmed: 19944453
Gynecol Oncol. 2010 Jan;116(1):10-4
pubmed: 19875158
Brachytherapy. 2012 Jan-Feb;11(1):58-67
pubmed: 22265439
J Contemp Brachytherapy. 2015 Jan;6(4):362-70
pubmed: 25834580
Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):211-9
pubmed: 10219816
Lancet. 2010 Mar 6;375(9717):816-23
pubmed: 20206777
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e631-8
pubmed: 21640520
Gynecol Oncol. 2007 Jul;106(1):215-20
pubmed: 17482665
Gynecol Oncol. 2005 Sep;98(3):434-8
pubmed: 16005498
Gynecol Oncol. 2004 Mar;92(3):744-51
pubmed: 14984936